Ainos Inc ( (AIMD) ) has released its Q4 earnings. Here is a breakdown of the information Ainos Inc presented to its investors.
Ainos, Inc., headquartered in San Diego, California, is a company that develops innovative medical and healthcare solutions using its proprietary AI Nose and VELDONA® technologies, focusing on AI-driven telehealth solutions and oral therapeutics for both humans and animals.
In its latest earnings report, Ainos, Inc. highlighted a strategic shift from COVID-19 antigen rapid tests to advancing its VELDONA® and AI Nose programs. The company reported significant developments in its AI Nose technology, including the launch of Ainos Flora for women’s health and the detection of volatile organic compounds in industrial settings. Additionally, Ainos is progressing with its VELDONA® drug development pipeline, focusing on clinical studies for HIV oral warts and Sjögren’s syndrome.
Key financial metrics revealed a decline in revenue to $20,729 for 2024, primarily due to decreased sales of COVID-19 antigen rapid test kits. However, the company managed to reduce its cost of revenues significantly, narrowing its gross loss. Operating expenses increased slightly, driven by investments in research and development, while selling, general, and administrative expenses saw a decrease. The net loss for the year was $14,863,161, reflecting the company’s ongoing strategic transition.
Looking ahead, Ainos, Inc. remains committed to accelerating innovation and expanding its intellectual property portfolio. The company aims to reinforce its leadership in AI Nose development and immunotherapy, with plans to increase research and development spending while maintaining financial flexibility. Management expresses confidence in achieving sustained growth through strategic partnerships and diversification of revenue sources.